Publications by authors named "Norikazu Masuda"

100Publications

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.

Breast Cancer Res Treat 2020 Apr 5;180(3):687-694. Epub 2020 Mar 5.

Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05580-yDOI Listing
April 2020

Breast metastasis from rectal cancer with BRAF V600E mutation: a case report with a review of the literature.

Clin J Gastroenterol 2020 Apr 3;13(2):153-157. Epub 2019 Sep 3.

Department of Gastroenterology and Hepatology, National Hospital Organization, Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, Osaka, 540-0006, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-019-01035-0DOI Listing
April 2020

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Breast Cancer 2019 09 24;26(5):637-650. Epub 2019 May 24.

Department of Breast Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00970-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694088PMC
September 2019

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Capecitabine for primary breast cancer.

Oncotarget 2017 Dec 6;8(67):110739-110740. Epub 2017 Dec 6.

Masakazu Toi: Breast Cancer Unit, Kyoto University Hospital, Breast Surgery, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762279PMC
December 2017

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.

Breast Cancer 2018 Jan 31;25(1):108-117. Epub 2017 Aug 31.

Department of Breast Oncology, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0798-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741785PMC
January 2018

Adjuvant Capecitabine for Breast Cancer.

N Engl J Med 2017 08;377(8):791-2

Chuo University, Tokyo, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1708487DOI Listing
August 2017

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

J Glob Oncol 2017 Aug 11;3(4):289-303. Epub 2017 Apr 11.

, Aichi Cancer Center Hospital, Nagoya; , National Hospital Organization, Osaka National Hospital, Osaka; , Saitama Cancer Center, Saitama; , Sagara Hospital, Kagoshima City; , Chiba Cancer Center, Chiba, Japan; , Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine; , Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; , Seoul National University Bundang Hospital, Seongnam; , National Cancer Center, Goyang, Republic of Korea; and , Pfizer, La Jolla, CA; , , and , Pfizer, New York, NY; and , Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2016.008318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560465PMC
August 2017

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

J Clin Oncol 2017 Sep 3;35(25):2875-2884. Epub 2017 Jun 3.

George W. Sledge Jr., Stanford University, Stanford; Han Koh, Kaiser Permanente Medical Group, Bellflower, CA; Masakazu Toi, Kyoto University; Kenichi Inoue, Saitama Cancer Center, Saitama; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Patrick Neven, Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium; Joohyuk Sohn, Yonsei Cancer Center, Seoul, Korea; Xavier Pivot, CHU de Besancon Hopital Jean Minjoz, Besancon Cedex; Nawel Bourayou, Eli Lilly, Paris, France; Olga Burdaeva, Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation; Meena Okera, Adelaide Cancer Centre, Adelaide, Australia; Peter A. Kaufman, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Eva-Maria Grischke, Universitätsklinikum Tübingen Frauenklinik, Tübingen, Germany; Martin Frenzel, Yong Lin, and Ian C. Smith, Eli Lilly, Indianapolis, IN; Susana Barriga, Eli Lilly, Madrid; and Antonio Llombart-Cussac, Hospital Arnau Vilanova, Valencia, Spain.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7585
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7585DOI Listing
September 2017

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

N Engl J Med 2017 08 4;377(6):523-533. Epub 2017 Jun 4.

From the Memorial Sloan Kettering Cancer Center, New York (M.R.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Medical University of Gdańsk, Gdańsk, Poland (E.S.); National Cancer Center-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.X.), and the First Hospital of Jilin University, Changchun (W.L.) - both in China; Basser Center, University of Pennsylvania, Philadelphia (S.M.D.); National Hospital Organization, Osaka National Hospital, Osaka, Japan (N.M.); Institut Gustave Roussy, Villejuif, France (S.D.); Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston (N.T.); Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester (A.A.), and AstraZeneca, Macclesfield (S.R.) - both in the United Kingdom; AstraZeneca, Gaithersburg, MD (W.W., C.G.); and University of Padua and Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1706450DOI Listing
August 2017

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

N Engl J Med 2017 06;376(22):2147-2159

From the National Hospital Organization Osaka National Hospital, Osaka (N.M.), Hiroshima City Hiroshima Citizens Hospital, Hiroshima (S. Ohtani), Kyoto Prefectural University of Medicine (I.Y.), and Graduate School of Medicine, Kyoto University (M.T.), Kyoto, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital (K.K.), and Chuo University (Y.O.), Tokyo, Gunma Prefectural Cancer Center, Ota (Y.Y.), National Hospital Organization Kyushu Cancer Center, Fukuoka (S. Ohno), Hyogo Cancer Center, Akashi (S.T.), National Hospital Organization Shikoku Cancer Center, Matsuyama (K.A.), Aichi Cancer Center Hospital, Nagoya (H.I.), and Tohoku University, Sendai (H.S.) - all in Japan; and Yeungnam University Hospital, Daegu (S.-J.L.), Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.-H.I.), Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine (S.-A.I.), Severance Hospital (B.-W.P.) and Gangnam Severance Hospital (J.J.), Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Korea University Guro Hospital (A.K.), and Korea University Anam Hospital (K.-H.P.), Seoul, and National Cancer Center, Goyang-si (E.-S.L.) - all in South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612645DOI Listing
June 2017

Evaluation of ALDH1 expression in ipsilateral breast cancer recurrence.

Oncol Lett 2017 Mar 27;13(3):1071-1077. Epub 2016 Dec 27.

Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2016.5538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403634PMC
March 2017

Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.

Hum Pathol 2017 06 20;64:145-155. Epub 2017 Apr 20.

Department of Pathology, National Hospital Organization, Osaka National Hospital, Osaka, 5400006, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2017.04.004DOI Listing
June 2017

[A Case of Recurrent Breast Cancer with Adrenal Metastasis Resected Using Laparoscopic Surgery].

Gan To Kagaku Ryoho 2016 Nov;43(12):2035-2037

Dept. of Surgery, National Hospital Organization Osaka National Hospital.

View Article

Download full-text PDF

Source
November 2016

Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.

Jpn J Clin Oncol 2016 Dec 8;46(12):1088-1094. Epub 2016 Sep 8.

Division of Medical Oncology, Department of Medicine, Saitama University International Medical Center, Saitama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyw127DOI Listing
December 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society.

Breast Cancer 2016 Jan 30;23(1):73-77. Epub 2015 Sep 30.

Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-015-0640-9DOI Listing
January 2016

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Cancer Chemother Pharmacol 2015 Oct 8;76(4):739-50. Epub 2015 Aug 8.

Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2826-4DOI Listing
October 2015

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.

Support Care Cancer 2015 Oct 3;23(10):2891-8. Epub 2015 Mar 3.

Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-015-2654-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552775PMC
October 2015